Lobular American Research Consortium
Lobular American Research Consortium is a privately held, Aurora, U.S.-based research organization founded in 2026 to advance diagnosis of lobular histology (consistent with invasive lobular carcinoma). It employs 11–50 staff, is led by founder Flora Migyanka, and has received $250,000 in seed funding from the Dynami Foundation.
- Company typePrivate
- Founded2026
- HeadquartersAurora, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Lobular American Research Consortium firmographics
Firmographics- Name
- Lobular American Research Consortium
- Website
- https://larcilc.org
- Company type
- Private
- Founded year
- 2026
- Headcount range
- 11–50 employees
- Short description
- Lobular American Research Consortium is a privately held, Aurora, U.S.-based research organization founded in 2026 to advance diagnosis of lobular histology (consistent with invasive lobular carcinoma). It employs 11–50 staff, is led by founder Flora Migyanka, and has received $250,000 in seed funding from the Dynami Foundation.
- Ownership category
- akta.pro rank
Lobular American Research Consortium industry classification
Industry- Product category
- Oncology Research Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715), Professional Organizations (813920)
- SIC
- Services-Membership Organizations (8600), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)
Keywords
Where Lobular American Research Consortium is headquartered
LocationHeadquarters
- HQ city
- Aurora
- HQ country
- United States
- HQ region
- North America
Markets served
Lobular American Research Consortium business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D
Lobular American Research Consortium product offering
Product offeringCore offering
Lobular American Research Consortium is a private research consortium whose stated aim is to establish the diagnosis of lobular histology, with a focus on invasive lobular carcinoma (ILC) research. The organization operates as a collaborative research entity headquartered in Aurora, United States, coordinating efforts related to lobular breast cancer histology and diagnostic standardization.
Differentiator
Problem solved
Functional benefit
Products and services
- Lobular Histology Research Program
Companies that use Lobular American Research Consortium
Customer profileIdeal customer profiles1 record
Lobular American Research Consortium technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Lobular American Research Consortium competitors and assessment
Company assessmentBroad incumbents
- American Cancer Society: The American Cancer Society funds and conducts broad cancer research including breast cancer, and operates as a large incumbent in the disease research and support space. Comparable as a scale-relevant peer in cancer-focused research funding.
- Susan G. Komen: Susan G. Komen is the largest breast cancer-specific nonprofit, funding research, advocacy, and patient support across all breast cancer subtypes including lobular. It is a broad incumbent whose programs compete with and absorb much of the donor attention LARC must compete for.
- Breast Cancer Research Foundation (BCRF): BCRF is a leading breast cancer research grantmaker funding investigator-driven research across histology subtypes, including lobular. It is a broad incumbent funder and research convener that LARC may ultimately seek funding or partnership with.
- National Cancer Institute (NCI): The NCI is the U.S. federal government's principal agency for cancer research, including breast and lobular carcinoma. Relevant as a peer funder and research agenda-setter that disease-focused consortia frequently partner with or compete against for talent and trials.
Emerging players
- PROMISE Foundation: The PROMISE Foundation is a peer nonprofit supporting lobular breast cancer research, expanding genomic understanding of metastatic progression. It is one of the closest niche nonprofit peers actively funding lobular research.
- Bonnie J. Addario Lung Cancer Foundation / GO2 for Lung Cancer: GO2 Foundation is a disease-focused research and advocacy nonprofit working in lung cancer. Comparable as a model for how a dedicated histology/organ-focused nonprofit can consolidate research, patient navigation, and consortium-style collaboration.
- Triple Negative Breast Cancer Foundation: The Triple Negative Breast Cancer Foundation is a subtype-focused breast cancer nonprofit that funds research and education for a specific histology. Highly relevant precedent for how a narrowly-scoped breast cancer nonprofit organizes research, advocacy, and fundraising.
Direct peers
- Metastatic Breast Cancer Alliance: The Metastatic Breast Cancer Alliance is a coalition of nonprofits, industry, and patient advocates working on metastatic breast cancer, including lobular subtypes. It is highly comparable to LARC in terms of consortium structure and breast cancer research focus.
- Lobular Breast Cancer Alliance: The Lobular Breast Cancer Alliance is a nonprofit advocacy and research coalition dedicated specifically to invasive lobular carcinoma, making it the most directly comparable peer to LARC's lobular histology mission. It shares both the disease focus and the consortium-style multi-stakeholder model.
Market position
Customer concentration
Lobular American Research Consortium social profiles
Digital presenceLobular American Research Consortium financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lobular American Research Consortium leadership team
Management profileNumber of profiles
Profiles1 record
Lobular American Research Consortium funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lobular American Research Consortium M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lobular American Research Consortium
What does Lobular American Research Consortium do?
Lobular American Research Consortium is a private research consortium whose stated aim is to establish the diagnosis of lobular histology, with a focus on invasive lobular carcinoma (ILC) research. The organization operates as a collaborative research entity headquartered in Aurora, United States, coordinating efforts related to lobular breast cancer histology and diagnostic standardization.
When was Lobular American Research Consortium founded?
Lobular American Research Consortium was founded in 2026. It employs 11 to 50 people.
Where is Lobular American Research Consortium based?
Lobular American Research Consortium is headquartered in Aurora, United States, in the North America region.
Who are Lobular American Research Consortium's main competitors?
Broad incumbents on record are American Cancer Society, Susan G. Komen, Breast Cancer Research Foundation (BCRF) and National Cancer Institute (NCI). Emerging players are PROMISE Foundation, Bonnie J. Addario Lung Cancer Foundation / GO2 for Lung Cancer and Triple Negative Breast Cancer Foundation. Direct peers are Metastatic Breast Cancer Alliance and Lobular Breast Cancer Alliance.
Does Lobular American Research Consortium have an API?
No public API is recorded for Lobular American Research Consortium.
What industry is Lobular American Research Consortium in?
Lobular American Research Consortium's product category is Oncology Research Services. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS). Its NAICS code is 5417 and its SIC code is 8600.